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Apropos of Dr Brossi and co-workers’ paper, 
‘Carbamate analogues of ( - )physostigmine: in 
vitro inhibition of acetyl- and butyrylcholinester- 
ase’ [(4 July 1988) FEBS Lett. 234, 127-130: 
received 19 April 19881, there are some details that 
I would like to discuss. Our Italian patent on 
(-)physostigmine analogs dates 1984 (CNR Pa- 
tent 47780-A84); the European Patent Application 
(no.85101945.5), dates 22 February 1985; the first 
US Patent Application (no.705,009) dates 25 
February 1985 and the second US Patent Applica- 
tion (no.909,025) dates 17 September 1986. 
In 1985, Whelpton and Moore published the 
dimethylphysostigmine (also called N- 
methylphysostigmine), the N-ethyl homologue and 
the N-propyl homologue [(14 June 1985) J. 
Chromatogr. Biomed. Appl. 341, 361-3711. In 
1986 Dr A. Brossi published N-methyl- 
physostigmine as an inhibitor of AChE [(1986) 
FEBS Lett. 201, 190-192: received 17 April 19861 
with no mention of the previous work by the 
British investigators (Whelpton and Moore). The 
dimethylphysostigmine had been reported as an oil 
characterized by an inhibitory activity much 
stronger than physostigmine itself. Relative poten- 
cy 450%. Each point was the mean of 4-8 assays. 
In 1987 our group published a study on 
physostigmine analogs with particular reference to 
heptylphysostigmine and its effects on behavioural 
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processes [(1987) Pharmacol. Biochem. Behav. 26, 
625-629: received July 19861. 
In 1987 (received 20 October 1987), we decided 
to submit a new article on physostigmine analogs 
which was published in March 1988 [(1988) Biom- 
ed. Biochim. Acta 47, 285-2881. In our work, the 
dimethylphysostigmine (also called N- 
methylphysostigmine) was described as a 
crystalline product less potent as AChE inhibitor 
than physostigmine itself, and we actually cited Dr 
Brossi’s previous work in FEBS Letters. 
In 1988 (in FEBS Lett.: received 19 April 1988), 
Dr Brossi’s group published again the 
methylphysostigmine, ‘Carbamate analogues of 
( - )physostigmine: in vitro inhibition of acetyl- 
and butyrylcholinesterase’; this time the com- 
pound was described as crystalline and had lost 
part of its inhibition: now it was a less potent in- 
hibitor than physostigmine: the relative potency 
was only the 6%. No mention of their previous 
work, where dimethylphysostigmine was described 
as a more potent inhibitor than physostigmine 
itself, and no mention of our previous work. In 
this paper, octylphysostigmine was also reported; 
no mention of our heptylphysostigmine. It is cer- 
tainly surprising the synthesis of octylphysostig- 
mine (or octylcarbamoylphysostigmine). As a 
matter of fact our group (biochemists, psycho- 
pharmacologists, psychobiologists, . . .) needed to 
synthesise - and to test for enzymatic inhibitory 
activity, passive avoidance and toxicity - many 
alkyl derivatives in order to decide that heptyl- 
physostigmine was the drug of choice. 
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